APA (7th ed.) Citation

AS, S., BA, D., S, N., A, A., S, I., N, O., . . . NC, M. (2026). Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma. Science translational medicine, 18(851), eadx1799. https://doi.org/10.1126/scitranslmed.adx1799

Chicago Style (17th ed.) Citation

AS, Sperling, et al. "Efficacy and Safety of Durcabtagene Autoleucel in a Phase 1 Trial for Patients with Relapsed/refractory Multiple Myeloma." Science Translational Medicine 18, no. 851 (2026): eadx1799. https://doi.org/10.1126/scitranslmed.adx1799.

MLA (9th ed.) Citation

AS, Sperling, et al. "Efficacy and Safety of Durcabtagene Autoleucel in a Phase 1 Trial for Patients with Relapsed/refractory Multiple Myeloma." Science Translational Medicine, vol. 18, no. 851, 2026, p. eadx1799, https://doi.org/10.1126/scitranslmed.adx1799.